Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Role of AP-2a/AP-2b transcription factors in the adult epidermis.

ABSTRACT: To investigate the effects of inactivation of the transcription factors AP-2a and/or AP-2b in the adult mouse skin.

ORGANISM(S): Mus musculus

PROVIDER: GSE248372 | GEO | 2023/12/20

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Transcription profiling of mouse LE-AP-2a mutants vs. wild-type P0 littermate lenses to investigate cell autonomous roles for AP-2alpha in lens vesicle separation and maintenance of the lens epithelial cell phenotype.

Project description:This is a comparative microarray analysis of LE-AP-2a mutants vs. wild-type P0 littermate lenses. This analysis revealed differential gene expression of 415 mRNAs, including reduced expression of genes important for maintaining lens epithelial cell phenotype, such as E-cadherin. Experiment Overall Design: Biological triplicates of mouse lenses were analyzed (three wild-type lens samples and three Le-AP-2 mutant samples)

2009-01-31 | E-GEOD-14536 | biostudies-arrayexpress

NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)

Project description:Study 07-PIR-02 is a Phase 2 study designed to evaluate the safety and efficacy of NKTR-102 (PEG-irinotecan) for the treatment of patients with colorectal cancer (CRC). The study is comprised of two sequential components - Phase 2a and Phase 2b. The Phase 2a portion is an open-label, dose-finding trial in multiple solid tumor types that are refractory to standard curative or palliative therapies. The primary endpoint of the Phase 2a is to establish the /recommended Phase 2 Dose (RPTD) of NKTR-102 by measuring the frequency of Dose Limiting Toxicity (DLT). The Phase 2b portion is an open-label, randomized, two-arm study in patients with second-line metastatic colorectal cancer and study participants will be randomized (1:1) to receive either NKTR-102 and cetuximab or irinotecan and cetuximab. The primary endpoint of the Phase 2b portion of the trial is progression-free survival. Secondary endpoints for both the Phase 2a and 2b portion include response rate, response duration, overall survival, standard pharmacokinetics, and incidence of toxicities, including diarrhea and neutropenia.

| 2049422 | ecrin-mdr-crc

Brassica rapa subsp. rapa cultivar:BY10-2A and BY10-2B

Project description:Brassica rapa subsp. rapa cultivar:BY10-2A and BY10-2B Raw sequence reads

| PRJNA552762 | ENA

Streptococcus equinus 2B strain:2B

Project description:Streptococcus equinus 2B strain:2B Genome sequencing and assembly

| PRJNA223471 | ENA

Shigella flexneri 2a strain:serotype 2a

Project description:Shigella flexneri 2a strain:serotype 2a Assembly

| PRJNA789735 | ENA

Shigella flexneri 2a strain:2a

Project description:Shigella flexneri 2a strain:2a Genome sequencing and assembly

| PRJNA379672 | ENA

Expression Data from YUGEN8 parental cell line and its clonally related isogenic variants Clone 1A, Clone 2A, and Clone 2B hereby labeled as GEN, Cl.1A, Cl.2A, and Cl.2B respectively

Project description:Expression Data from YUGEN8 parental cell line and its clonally related isogenic variants Clone 1A, Clone 2A, and Clone 2B hereby labeled as GEN, Cl.1A, Cl.2A, and Cl.2B respectively

| PRJNA759565 | ENA

high-throughput sequencing of circRNAs in T-BEAS-2B cells and C-BEAS-2B cells

Project description:We report the differential expression of circRNAs between T-BEAS-2B cells (cadmium-transformed BEAS-2B cells) and C-BEAS-2B cells (passage-matched control BEAS-2B cells) by high-throughput sequencing. T-BEAS-2B cells are BEAS-2B cells transformed by cadmium at 2.0 μM for twenty weeks, and C-BEAS-2B cells are their passage-matched control. RNAs were sequenced on Illumina HiSeq Xten platform in triplicates, and expressions of circRNAs were calculated by TPM (transcripts per kilobase of exon model per million mapped reads). Clean data per sample exceeds 10 GB. We find 235 significantly up-regulated circRNAs and 271 significantly down-regulated circRNAs in T-BEAS-2B cells relative to C-BEAS-2B cells. Our work provides clues and evidence for exploring the mechanism of circRNAs in cadmium carcinogenesis.

2024-01-26 | GSE165549 | GEO

3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

Project description:This phase I trial is studying the best dose of 3-AP and the side effects of giving 3-AP together with gemcitabine in treating patients with advanced solid tumors or lymphoma. Drugs used in chemotherapy, such as 3-AP and gemcitabine (GEM), work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. 3-AP may help gemcitabine kill more cancer cells by making the cells more sensitive to the drug. 3-AP may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

| 2026481 | ecrin-mdr-crc

Transcriptome of Actinosynnema pretiosum ATCC 31280 under exogenous supplement of AP-3

Project description:In search of AP-3 resistant genes, ATCC 31280△ansaA (inactivation of ansamitocin pksA, in avoiding of the interruption of endogenous generated AP-3) were cultured under the addition of 0, 50, 100 and 200 mg/L exogenous AP-3 for 24 h and collected, for strains under 200 mg/L AP-3, samples after 48 h and 72 h were also collected, and the RNA samples were collected and sent for sequencing.

2019-11-06 | GSE139930 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data